Mycofenolaatmofetil Accord (Mycophenolate Mofetil)

Mycophenolate Mofetil is converted to mycophenolic acid, which selectively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH). This inhibition blocks guanosine nucleotide synthesis, a critical step for DNA replication in activated T and B lymphocytes, thereby reducing their proliferation and dampening the immune response.

The dosing regimen for Mycofenolaatmofetil Accord is determined by the prescribing physician based on the patient’s clinical condition, weight, renal function, and concomitant therapies. Healthcare professionals tailor the dose to achieve the desired immunosuppressive effect while monitoring safety parameters.

Mycophenolate Mofetil is classified as Pregnancy Category X because it can cause fetal malformations and embryotoxicity. It is contraindicated in pregnant women and should be discontinued before conception. The drug is also excreted in breast milk, so breastfeeding is not recommended while receiving treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics for injectables), and necessary import documentation.

Compared with calcineurin inhibitors such as cyclosporine or tacrolimus, mycophenolate mofetil offers a different mechanism by targeting lymphocyte proliferation rather than cytokine production. It is often used in combination regimens to provide synergistic immunosuppression while potentially reducing the dose‑related toxicities of each individual agent.

Mycofenolaatmofetil Accord should be stored refrigerated at 2‑8 °C. Protect the vial from light, avoid freezing, and do not shake vigorously. If the product must be transported, maintain the cold chain using validated insulated containers with temperature monitoring to ensure product integrity.

The medication is supplied as a sterile injectable solution for intravenous infusion. Administration is performed by a qualified healthcare professional in a clinical setting, following aseptic technique. The infusion rate and volume are determined by the prescribing clinician based on the patient’s therapeutic plan.

Serious risks include severe infections (including opportunistic pathogens), development of malignancies such as lymphoproliferative disorders, hepatic failure, and profound bone‑marrow suppression leading to pancytopenia. Patients should be monitored closely for signs of infection, abnormal blood counts, and liver function abnormalities throughout therapy.

Mycofenolaatmofetil Accord is contraindicated in pregnant women, nursing mothers, and individuals with known hypersensitivity to mycophenolate mofetil or any component of the formulation. It should also be avoided in patients with severe uncontrolled infections or those receiving live vaccines due to heightened infection risk.